A plasmid DNA immunogen expressing fifteen protein antigens and complex virus-like particles (VLP+) mimicking naturally occurring HIV. (Q45371000)

13 December 2017

title

A plasmid DNA immunogen expressing fifteen protein antigens and complex virus-like particles (VLP+) mimicking naturally occurring HIV. (English)

1 reference

13 December 2017

Julianna Lisziewicz

1 reference

13 December 2017

Eszter Somogyi

1 reference

13 December 2017

Jianqing Xu

1 reference

13 December 2017

Agnes Gudics

1 reference

13 December 2017

József Tóth

1 reference

13 December 2017

Attila L Kovács

1 reference

13 December 2017

Franco Lori

1 reference

13 December 2017

language of work or name

English

0 references

publication date

23 November 2010

1 reference

13 December 2017

1 reference

inferred from page(s)

published in

Vaccine

1 reference

13 December 2017

1 reference

13 December 2017

1 reference

13 December 2017

page(s)

744-753

1 reference

The qualitative nature of the primary immune response to HIV infection is a prognosticator of disease progression independent of the initial level of plasma viremia

13 December 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.11.019

Evidence for recombination of live, attenuated immunodeficiency virus vaccine with challenge virus to a more virulent strain.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.11.019

Efficacy of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by oncogenic HPV types (PATRICIA): final analysis of a double-blind, randomised study in young women

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.11.019

Quadrivalent vaccine against human papillomavirus to prevent high-grade cervical lesions

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.11.019

Effect of human papillomavirus 16/18 L1 viruslike particle vaccine among young women with preexisting infection: a randomized trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.11.019

Functional HIV-1 specific IgA antibodies in HIV-1 exposed, persistently IgG seronegative female sex workers

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.11.019

HIV-specific cytotoxic T-cells in HIV-exposed but uninfected Gambian women

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.11.019

Characterization of HIV-1-specific T-helper cells in acute and chronic infection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.11.019

Control of HIV despite the Discontinuation of Antiretroviral Therapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.11.019

Efficacy of a SHIV 89.6 proviral DNA vaccine against mucosal SIVmac239 challenge

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.11.019

HIV-1 vaccine-induced immunity in the test-of-concept Step Study: a case-cohort analysis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.11.019

Rational development of a stable liquid formulation for nanomedicine products

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.11.019

DermaVir: a novel topical vaccine for HIV/AIDS.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.11.019

Multiple determinants for growth of human immunodeficiency virus type 1 in monocyte-macrophages

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.11.019

Complementary antiviral efficacy of hydroxyurea and protease inhibitors in human immunodeficiency virus-infected dendritic cells and lymphocytes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.11.019

A community resource benchmarking predictions of peptide binding to MHC-I molecules

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.11.019

A systematic assessment of MHC class II peptide binding predictions and evaluation of a consensus approach

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.11.019

Reliable prediction of T-cell epitopes using neural networks with novel sequence representations

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.11.019

SV40-derived vectors provide effective transgene expression and inhibition of HIV-1 using constitutive, conditional,and pol III promoters.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.11.019

The advantage of early recognition of HIV-infected cells by cytotoxic T-lymphocytes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.11.019

Molecular Interactions between HIV-1 integrase and the two viral DNA ends within the synaptic complex that mediates concerted integration

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.11.019

Strategies used by human immunodeficiency virus that allow persistent viral replication

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.11.019

Self-limiting, cell type-dependent replication of an integrase-defective human immunodeficiency virus type 1 in human primary macrophages but not T lymphocytes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.11.019

Substrate sequence selection by retroviral integrase

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.11.019

Endocytosis of major histocompatibility complex class I molecules is induced by the HIV–1 Nef protein

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.11.019

HIV-1 Nef impairs MHC class II antigen presentation and surface expression

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.11.019

HIV-1 Nef protein protects infected primary cells against killing by cytotoxic T lymphocytes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.11.019

Brief report: absence of intact nef sequences in a long-term survivor with nonprogressive HIV-1 infection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.11.019

Importance of the nef gene for maintenance of high virus loads and for development of AIDS

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.11.019

A bivalent influenza VLP vaccine confers complete inhibition of virus replication in lungs

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.11.019

Optimization of a multi-gene HIV-1 recombinant subtype CRF02_AG DNA vaccine for expression of multiple immunogenic forms

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.11.019

Comparative immunogenicity in rhesus monkeys of multi-protein HIV-1 (CRF02_AG) DNA/MVA vaccines expressing mature and immature VLPs

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.11.019

Productive infection of dendritic cells by HIV-1 and their ability to capture virus are mediated through separate pathways.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.11.019

Nef interacts with the mu subunit of clathrin adaptor complexes and reveals a cryptic sorting signal in MHC I molecules

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.11.019

Nef-mediated resistance of human immunodeficiency virus type 1 to antiviral cytotoxic T lymphocytes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.11.019

Broad immunogenicity of a multigene, multiclade HIV-1 DNA vaccine boosted with heterologous HIV-1 recombinant modified vaccinia virus Ankara

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.11.019

Hierarchical targeting of subtype C human immunodeficiency virus type 1 proteins by CD8+ T cells: correlation with viral load

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.11.019

CD8+ T-cell responses to different HIV proteins have discordant associations with viral load

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.11.019

Phase-dependent immune evasion of herpesviruses

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.11.019

Polyvalent vaccines for optimal coverage of potential T-cell epitopes in global HIV-1 variants

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.11.019

Polyreactivity increases the apparent affinity of anti-HIV antibodies by heteroligation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.11.019

CD4+ T cells are required for secondary expansion and memory in CD8+ T lymphocytes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.11.019

Induction of potent human immunodeficiency virus type 1-specific T-cell-restricted immunity by genetically modified dendritic cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.11.019

Advances in methods for the production, purification, and characterization of HIV-1 Gag-Env pseudovirion vaccines.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.11.019

Construction and analysis of deletion mutations in the U5 region of Moloney murine leukemia virus: effects on RNA packaging and reverse transcription.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.11.019

Induction of vigorous cytotoxic T-lymphocyte responses by live attenuated simian immunodeficiency virus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.11.019

inferred from DOI database lookup

7 January 2021

based on heuristic

Identifiers

DOI

10.1016/J.VACCINE.2010.11.019

1 reference

13 December 2017

1 reference